Total Payments
$9,588
2024 Payments
$3,232
Companies
19
Transactions
456
Medicare Patients
2,063
Medicare Billing
$160,508
Payment Breakdown by Category
Food & Beverage$8,948 (93.3%)
Education$639.62 (6.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,948 | 446 | 93.3% |
| Education | $639.62 | 10 | 6.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $2,483 | 120 | $0 (2024) |
| ABBVIE INC. | $1,703 | 89 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $995.69 | 42 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $995.42 | 60 | $0 (2024) |
| Lilly USA, LLC | $756.30 | 30 | $0 (2024) |
| PFIZER INC. | $476.64 | 27 | $0 (2024) |
| Sun Pharmaceutical Industries Inc. | $348.28 | 10 | $0 (2023) |
| Amgen Inc. | $309.02 | 18 | $0 (2024) |
| Arcutis Biotherapeutics, Inc. | $267.32 | 7 | $0 (2024) |
| GENZYME CORPORATION | $254.40 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,232 | 148 | Janssen Biotech, Inc. ($840.26) |
| 2023 | $3,800 | 180 | Janssen Biotech, Inc. ($1,225) |
| 2022 | $1,940 | 92 | ABBVIE INC. ($584.08) |
| 2021 | $615.01 | 36 | AbbVie Inc. ($230.63) |
All Payment Transactions
456 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Lilly USA, LLC | — | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| 12/16/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $24.58 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $20.67 | General |
| Category: Dermatology | ||||||
| 12/10/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $16.45 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $11.31 | General |
| Category: Dermatology | ||||||
| 11/26/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $20.63 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $5.99 | General |
| Category: Immunology | ||||||
| 11/22/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $18.18 | General |
| Category: DERMATOLOGY | ||||||
| 11/21/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $10.75 | General |
| Category: Immunology | ||||||
| 11/18/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $25.21 | General |
| Category: Immunology | ||||||
| 11/15/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $9.08 | General |
| Category: Dermatology | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $13.24 | General |
| Category: Dermatology | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $6.12 | General |
| Category: Dermatology | ||||||
| 11/07/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $105.67 | General |
| Category: Immunology | ||||||
| 11/05/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $19.86 | General |
| Category: Immunology | ||||||
| 10/29/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $22.67 | General |
| 10/22/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $27.30 | General |
| Category: Immunology | ||||||
| 10/21/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $22.40 | General |
| Category: IMMUNOLOGY | ||||||
| 10/16/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $15.49 | General |
| Category: Immunology | ||||||
| 10/14/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Education | In-kind items and services | $99.00 | General |
| Category: Immunology | ||||||
| 10/14/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $33.61 | General |
| Category: Immunology | ||||||
| 10/11/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $28.30 | General |
| Category: Immunology | ||||||
| 10/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $15.72 | General |
| Category: Immunology | ||||||
| 10/09/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $14.70 | General |
| Category: Inflammation | ||||||
| 10/08/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $28.33 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 562 | 1,279 | $251,630 | $59,917 |
| 2022 | 18 | 597 | 1,087 | $225,393 | $52,550 |
| 2021 | 8 | 458 | 1,202 | $204,680 | $25,698 |
| 2020 | 5 | 446 | 1,335 | $218,798 | $22,343 |
Total Patients
2,063
Total Services
4,903
Medicare Billing
$160,508
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2023 | 18 | 35 | $34,228 | $10,734 | 31.4% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 65 | 109 | $33,272 | $7,750 | 23.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 49 | 75 | $24,832 | $6,048 | 24.4% |
| 96574 | Application of light with debridement to destroy precancer skin growth | Office | 2023 | 18 | 32 | $24,428 | $5,985 | 24.5% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 31 | 50 | $22,510 | $5,572 | 24.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 63 | 98 | $22,936 | $5,265 | 23.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 41 | 41 | $17,599 | $3,651 | 20.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 75 | 108 | $19,223 | $3,206 | 16.7% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 66 | 574 | $10,363 | $2,704 | 26.1% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 43 | 52 | $14,217 | $2,564 | 18.0% |
| 17111 | Destruction of skin growth, 15 or more growths | Office | 2023 | 20 | 25 | $8,857 | $2,315 | 26.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 35 | 35 | $10,080 | $1,993 | 19.8% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 13 | 14 | $4,711 | $1,082 | 23.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 13 | 16 | $2,352 | $551.68 | 23.5% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 12 | 15 | $2,023 | $496.29 | 24.5% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2022 | 17 | 27 | $26,475 | $8,384 | 31.7% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 44 | 55 | $24,344 | $6,180 | 25.4% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 59 | 85 | $25,331 | $5,808 | 22.9% |
| 96574 | Application of light with debridement to destroy precancer skin growth | Office | 2022 | 17 | 23 | $17,185 | $4,056 | 23.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 67 | 67 | $19,042 | $3,892 | 20.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 48 | 69 | $16,019 | $3,762 | 23.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 26 | 43 | $13,968 | $3,573 | 25.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 37 | 37 | $15,568 | $3,361 | 21.6% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 60 | 76 | $13,258 | $2,146 | 16.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 54 | 408 | $7,301 | $1,710 | 23.4% |
About Mark Davis, PA
Mark Davis, PA is a Surgical healthcare provider based in Lake Oswego, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1508928714.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Mark Davis, PA has received a total of $9,588 in payments from pharmaceutical and medical device companies, with $3,232 received in 2024. These payments were reported across 456 transactions from 19 companies. The most common payment nature is "Food and Beverage" ($8,948).
As a Medicare-enrolled provider, Davis has provided services to 2,063 Medicare beneficiaries, totaling 4,903 services with total Medicare billing of $160,508. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Surgical
- Other Specialties Medical
- Location Lake Oswego, OR
- Active Since 12/14/2006
- Last Updated 12/24/2024
- Taxonomy Code 363AS0400X
- Entity Type Individual
- NPI Number 1508928714
Products in Payments
- TREMFYA (Drug) $1,747
- SKYRIZI (Biological) $1,193
- Sotyktu (Drug) $995.69
- REMICADE (Biological) $735.72
- COSENTYX (Drug) $649.77
- RINVOQ (Biological) $419.70
- DUPIXENT (Biological) $380.61
- EUCRISA (Drug) $372.16
- COSENTYX (Biological) $345.65
- TALTZ (Drug) $330.44
- Otezla (Drug) $309.02
- VTAMA (Drug) $233.69
- Bimzelx (Biological) $204.43
- OLUMIANT (Drug) $189.63
- ADBRY (Biological) $159.17
- Absorica LD (Drug) $103.01
- Winlevi (Drug) $92.00
- LITFULO (Drug) $68.22
- OPZELURA (Drug) $62.41
- ILUMYA (Biological) $53.28
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.